Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | F10 | P00742 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL683537 | 0.92 | ACE (0.81) | ACELMNASMN1; SMN2MEN1USP2 | |
| SCHEMBL7266938 | 0.92 | ACE (0.81) | ACELMNASMN1; SMN2MEN1USP2 | |
| SCHEMBL7324203 | 0.90 | ACE (0.84) | ACELMNASMN1; SMN2F2F10 | |
| SCHEMBL18579086 | 0.90 | ACE (0.84) | ACELMNASMN1; SMN2F2F10 | |
| SCHEMBL682331 | 0.90 | ACE (0.84) | ACELMNASMN1; SMN2F2F10 | |
| SCHEMBL9439053 | 0.89 | ACE (0.76) | ACELMNASMN1; SMN2MEN1USP2 | |
| SCHEMBL683530 | 0.88 | ACE (0.64) | ACELMNASMN1; SMN2 | |
| SCHEMBL7327929 | 0.87 | ACE (0.63) | ACELMNASMN1; SMN2 | |
| SCHEMBL683526 | 0.86 | ACE (0.61) | ACELMNASMN1; SMN2MEN1USP2 | |
| Lisinopril Anhydrous SCHEMBL5411625 | 0.86 | ACE (0.80) | ACELMNASMN1; SMN2MEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | ACE 4514/4885LMNA 3688/4885SMN1; SMN2 138/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | ACE 6/4885LMNA 2155/4885SMN1; SMN2 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.